The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--bit.bio, a synthetic biology company focused on human cells, has achieved a milestone in the manufacture of human cells. Based on their opti-ox TM 1 - ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

Restructuring the pricing of bit.bio’s human cells is expanding access across the life sciences sector, enabling scientists in academia, biotech, and pharma to adopt new approach methodologies (NAMs) ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and ...

LONDON, Jan. 9, 2026 /PRNewswire/ -- M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering ...

CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...

In the mid-2000s, Mark Kotter, MD, PhD, was running a lab studying oligodendrocytes when he started his training in neurosurgery. As a neurosurgeon, he had access to rare brain samples and was able to ...

CAMBRIDGE, England, February 19, 2026--(BUSINESS WIRE)--Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to ...